Loading…
This event has ended. Visit the official site or create your own event on Sched.

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Pricing- Reimbursement and Access [clear filter]
Wednesday, June 29
 

2:00pm EDT

#336: Effect of International Reference Pricing on Planning for Global New Product Launches
Limited Capacity seats available

Component Type: Session
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-16-597-L04-P; CME 1.25; IACET 1.25; PDU 1.25 PMI 2166-000184; RN 1.25

As more countries adopt cost containment strategies, it becomes increasing difficult to plan and execute successful, global launches of new drugs. This session will provide an overview of how to plan a successful launch given these challenges.

Learning Objectives

Identify the variables which influence the price of new drugs; Explain how international reference pricing affects optimal launch sequence; Recognize the other considerations (e.g., country scope, intellectual property, clinical plan) when planning a successful launch.

Chair

Matthew Steven Curin, PharmD

Speaker

What Every Project Manager Should Know about HTA and Pricing
Claire Corry, MS

Mapping the Global Launch Sequence in a Partnership
Nathan J. Murray

Practical Application of Global Launch Best Practices
Matthew Steven Curin, PharmD



Chair
avatar for Matthew Curin

Matthew Curin

Executive Director, Program Management, Epizyme
Matt has been working in the pharmaceutical industry for almost 20 years, spending the first 8 years in clinical manufacturing before moving into project management in 2007. Since then, Matt has provided project, program, and portfolio management leadership in clinical development... Read More →

Speakers
avatar for Claire Corry

Claire Corry

Director, Global Project and Alliance Management, Merck & Co., Inc.
Claire Corry currently is a Director in Global Project and Alliance Management at Merck and has been working in project and portfolio management roles for 15 years. Claire has a wealth of knowledge across all phases of drug development, working with both small molecules and biologics... Read More →
avatar for Nathan Murray

Nathan Murray

Global PRA Advisor, Autoimmune, Eli Lilly and Company
Currently lead a cross-functional (and multinational) team in the development of global price, reimbursement and access (PRA) strategy for both pre-launch and commercialized products. Primarily responsible for achieving acceptable access and reimbursement levels for patients and for... Read More →


Wednesday June 29, 2016 2:00pm - 3:15pm EDT
105AB Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
  Trk 02: Proj-Port Mgt-Strat Planning, Session

4:00pm EDT

#370: Pricing, Patient Access, and What’s Next for Today’s Biopharma and Devices
Limited Capacity seats available

Component Type: Forum
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-16-573-L04-P; CME 1.25; IACET 1.25; RN 1.25

Industry leaders, public payers, policy makers and issue experts provide insights into today’s heated debate about drug pricing, patient access and the policy battles ahead. This forum will offer engaging presentations, moderated discussion, and participant Q&A.

Learning Objectives

Identify key issues affecting the treatment pricing and patient access landscape; Describe how to apply potential models for determining a treatment’s value; Discuss ways to integrate new ideas for communicating a product’s rationale for patients, treaters and payers.

Chair

Jane Horvath, MHA

Speaker

Panelist
Matt Salo

Panelist
Michael Gray, MBA

Panelist
John Hoffman, MBA



Chair
avatar for Jane Horvath

Jane Horvath

Market Access Lead, 3D Communications
Jane Horvath, MHSA, leads 3D's Market Access and Value Communications team. Jane brings nearly 25 years of experience in health policy and reimbursement. She was Merck’s Executive Director of Health Policy and Reimbursement for a decade, Deputy Director of the RWJF project at Johns... Read More →

Speakers
avatar for Michael Gray

Michael Gray

Vice President and Chief Operating Officer, The Resource Group, Ascension
Michael has executive oversight and thought leadership responsibility for the ongoing development, implementation, and management of The Resource Group’s Strategic Direction. He spent seven years as President and CEO of Mercy Resource Management Inc., with responsibilities for Corporate... Read More →
avatar for John Hoffman

John Hoffman

Senior Director, Health Policy, Advocacy and Quality, Johnson & Johnson
As the Senior Director, Health Policy, Advocacy & Quality for the Strategic Customer Group at J&J North American Pharmaceuticals, John's responsibilities include ensuring unencumbered access to all J&J NA Pharma products for patients and physicians. The Strategic Customer Group develops... Read More →
avatar for Matt Salo

Matt Salo

Executive Director, National Association of Medicaid Directors
Matt Salo was named Executive Director of the National Association of Medicaid Directors in February 2011. The association represents all 56 of the nation’s state and territorial Medicaid Directors, and provides them with a strong unified voice in national discussions as well as... Read More →


Wednesday June 29, 2016 4:00pm - 5:15pm EDT
107AB Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA